Stock-Based Compensation | Stock-Based Compensation Shares Available for Issuance As of March 31, 2023 and December 31, 2022, 17,353,843 and 10,890,112 equity incentive awards remain available for issuance under the 2021 Plan, respectively. As of March 31, 2023 and December 31, 2022, 6,198,134 and 4,762,721 shares of common stock remain available for issuance under the ESPP. Stock Options The following is a summary of the Company’s stock option activity during the three months ended March 31, 2023: Stock Options (in thousands, except share and per share data) Number of Options Outstanding Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (1) Balances as of January 1, 2023 15,988,268 $ 4.11 6.79 $ 119,467 Exercised (1,659,193) 2.87 19,007 Forfeited (254,292) 5.60 Balances as of March 31, 2023 14,074,783 4.23 6.56 179,001 Vested and exercisable as of March 31, 2023 9,237,232 2.60 5.81 132,531 Vested and expected to vest as of March 31, 2023 14,091,466 $ 4.24 6.57 $ 179,038 _________________ (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the estimated fair value of the Company’s common stock. No stock options were granted during the three months ended March 31, 2023 and March 31, 2022. The aggregate grant-date fair value of options vested for the three months ended March 31, 2023 and 2022 was $2.2 million and $2.9 million, respectively. The intrinsic value of options exercised for the three months ended March 31, 2023 and 2022 was $19.0 million and $12.6 million, respectively. Restricted Stock Units Restricted stock unit activity during the three months ended March 31, 2023 was as follows: Number of Shares Weighted-Average Grant-Date Fair Value Per Share Unvested at January 1, 2023 23,366,355 $ 11.86 Granted 3,425,404 12.41 Vested (1,930,772) 12.53 Cancelled/forfeited (950,126) 14.10 Unvested at March 31, 2023 23,910,861 $ 11.79 The weighted-average grant date fair value of RSUs, granted during the three months ended March 31, 2023 and 2022 was $12.41 and $13.06, respectively. The aggregate grant-date fair value of RSUs, vested for the three months ended March 31, 2023 and 2022 was $24.2 million and $0.5 million, respectively. Employee Stock Purchase Plan (“ESPP”) The offering period that commenced on September 22, 2021, for which the accounting grant date was met in October 2021, ended on February 28, 2022, due to a decline in the Company’s stock price at the end of the purchase period, triggering a new offering period, as required by the ESPP plan documents. A new 24-month offering period commenced on March 1, 2022. This event was accounted for as a modification under U.S. GAAP in the first quarter of 2022, whereby the fair value of the ESPP offering was measured immediately before and after modification, resulting in incremental stock-based compensation expense of $3.6 million, which is being recognized over the new offering period, which is deemed to be the requisite service period. A new subsequent 24-month offering period commences on March 1 and September 1 of each fiscal year. The fair value of the ESPP offerings described above were estimated using the Black-Scholes option-pricing model as of the respective offering dates, using the following assumptions. These assumptions represent the grant date fair value inputs for new offerings which commenced during the three months ended March 31, 2023 and 2022, as well as updated valuation information as of the modification date for any offerings for which a modification occurred during the periods presented herein: Three Months Ended March 31, 2023 2022 Risk-free interest rates 4.83% to 5.13% 0.60% to 1.31% Expected term (in years) 0.5 to 2.0 years 0.5 to 2.0 years Volatility 48.9% to 59.5% 61.0% to 73.0% Dividend rate — % — % As the March 1, 2022 offering was accounted for as a modification to the October 2021 offering, the ESPP was fair valued immediately before and after modification on March 1, 2022 to assess the incremental fair value provided as a result of the modification. The inputs to the incremental fair value are included in the table above. Stock-Based Compensation Expense Stock-based compensation expense for stock options, RSUs, and the ESPP, included within the Condensed Consolidated Statements of Operations, net of amounts capitalized to internal-use software, as described in Note 4. Property and Equipment , was as follows: Three Months Ended March 31, (in thousands) 2023 2022 Customer support and operations $ 205 $ 93 Marketing 2,983 1,032 Technology and development 16,631 4,072 General and administrative 9,415 4,397 Total $ 29,234 $ 9,594 As of March 31, 2023, the total unamortized compensation cost related to all non-vested equity awards, including options and RSUs, was $258.7 million, which will be amortized over a weighted-average remaining requisite service period of approximately 2.9 years. As of March 31, 2023, the total unrecognized compensation expense related to the ESPP was $5.8 million, which is expected to be amortized over the next 1.9 years. The Company did not record a material income tax benefit related to stock-based compensation expense and stock option exercises, during the three months ended March 31, 2023 and 2022, since the Company currently maintains a full valuation allowance against its net deferred tax assets in the jurisdictions where material stock-based compensation expense charges are incurred, and stock option exercises occurred. |